Search

Your search keyword '"Fogelstrand, Linda"' showing total 40 results

Search Constraints

Start Over You searched for: Author "Fogelstrand, Linda" Remove constraint Author: "Fogelstrand, Linda" Publication Year Range Last 3 years Remove constraint Publication Year Range: Last 3 years
40 results on '"Fogelstrand, Linda"'

Search Results

2. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms

4. Characterization of Pediatric Acute Myeloid Leukemia With t(7;12)(q36;p13).

5. Targeting CD38 with monoclonal antibodies disrupts key survival pathways in paediatric Burkitt's lymphoma malignant B cells.

7. Precision Diagnostics in Myeloid Malignancies: Development and Validation of a National Capture-Based Gene Panel

8. Precision Diagnostics in Myeloid Malignancies: Development and Validation of a National Capture‐Based Gene Panel.

9. CD38 as a therapeutic target in pediatric Burkitt’s Lymphoma: insights from a comparative approach (Running title: Targeting CD38 in pediatric Burkitt's Lymphoma)

11. Feasibility to use whole-genome sequencing as a sole diagnostic method to detect genomic aberrations in pediatric B-cell acute lymphoblastic leukemia

12. P506: CLINICAL VALIDATION OF THE NORDIC GUIDELINES FOR GERMLINE TESTING IN MYELOID NEOPLASMS: RESULTS FROM A MULTI-CENTER PROSPECTIVE COHORT STUDY

13. P468: DETECTION AND CHARACTERIZATION OF RESIDUAL LEUKEMIC CELLS IN CHILDHOOD ACUTE MYELOID LEUKEMIA USING TARGETED DEEP SEQUENCING AND SINGLE CELL MULTI-OMICS

14. P513: MOLECULAR PATTERN BY AGE AND OVERALL SURVIVAL IN ACUTE MYELOID LEUKEMIA: A POPULATION-BASED STUDY FROM THE SWEDISH AML REGISTRY.

15. P422: TARGETING THE WT1MUT-MIR-193A TRANSCRIPTIONAL AXIS WITH INT-1B3, A NOVEL LIPID NANOPARTICLE-FORMULATED MIR-193A-3P MIMIC IN ACUTE MYELOID LEUKEMIA

16. Feasibility to use whole-genome sequencing as a sole diagnostic method to detect genomic aberrations in pediatric B-cell acute lymphoblastic leukemia

18. The Rise and Fall of Leukemia Clones in Longitudinal Samples from Diagnosis to Relapse in KMT2A-rearranged Infant and Childhood Leukemia

19. Targeting the WT1mut-Mir-193a Transcriptional Axis with INT-1B3, a Novel Lipid Nanoparticle-Formulated Mir-193a-3p Mimic in Acute Myeloid Leukemia

20. Duplex Sequencing Uncovers Recurrent Low-frequency Cancer-associated Mutations in Infant and Childhood KMT2A-rearranged Acute Leukemia

21. Mnx1 Induces Leukemia Transformation Through Altering Histone Methylation in a Model of Pediatric Acute Myeloid Leukemia with t(7;12)(q36;p13)

22. Targeting SAMHD1 with hydroxyurea in first‐line cytarabine‐based therapy of newly diagnosed acute myeloid leukaemia: Results from the HEAT‐AML trial

23. Fusion transcript analysis reveals slower response kinetics than multiparameter flow cytometry in childhood acute myeloid leukaemia

24. Human CD38 regulates B cell antigen receptor dynamic organization in normal and malignant B cells

25. A Study Protocol for Validation and Implementation of Whole-Genome and -Transcriptome Sequencing as a Comprehensive Precision Diagnostic Test in Acute Leukemias

26. Targeting SAMHD1 with hydroxyurea in first-line cytarabine-based therapy of newly diagnosed acute myeloid leukaemia : Results from the HEAT-AML trial

27. Duplex sequencing uncovers recurrent low-frequency cancer-associated mutations in infant and childhood KMT2A-rearranged acute leukemia

28. Molecular Measurable Residual Disease Assessment before Hematopoietic Stem Cell Transplantation in Pediatric Acute Myeloid Leukemia Patients: A Retrospective Study by the I-BFM Study Group

30. A Study Protocol for Validation and Implementation of Whole-Genome and -Transcriptome Sequencing as a Comprehensive Precision Diagnostic Test in Acute Leukemias

31. Fusion transcript analysis reveals slower response kinetics than multiparameter flow cytometry in childhood acute myeloid leukemia

32. A Study Protocol for Validation and Implementation of Whole-Genome and -Transcriptome Sequencing as a Comprehensive Precision Diagnostic Test in Acute Leukemias

33. The Relapse Mechanisms and Genomic Landscape Differ in KMT2A-r Pediatric Leukemia in Relation to Relapse Time

36. Chip-AML22 Master Protocol: An Open-Label Clinical Trial in Newly Diagnosed Pediatric De Novo Acute Myeloid Leukemia (AML) Patients Including a Linked Phase II Trial with Quizartinib in FLT3-ITD/ NPM1wt Patients - a Study By the NOPHO-DB-SHIP Consortium

38. Targeting the WT1mut-Mir-193aTranscriptional Axis with INT-1B3, a Novel Lipid Nanoparticle-Formulated Mir-193a-3pMimic in Acute Myeloid Leukemia

39. Influence of Nucleophosmin ( NPM1 ) Genotypes on Outcome of Patients With AML: An AIEOP-BFM and COG-SWOG Intergroup Collaboration.

40. Aberrant MNX1 expression associated with t(7;12)(q36;p13) pediatric acute myeloid leukemia induces the disease through altering histone methylation.

Catalog

Books, media, physical & digital resources